

## 15-YEAR SURVIVAL AND LOCAL CONTROL UPDATE: EARLY-STAGE BREAST CANCER IOERT

Moreno Moya A. C., García-Abad Oviedo P., De la Cruz Rodríguez M.I., Navarrete Torres A.C., Muñoz Fernández M., Rincón Olbes P., Rodríguez Pertierra M., Lozano Barriuso M.A., Blanco Rodríguez J.A., Calín Lorca A.

[andres\\_moreno95@hotmail.com](mailto:andres_moreno95@hotmail.com)

*S<sup>o</sup> Oncología Radioterápica, Hospital General Universitario Gregorio Marañón, Madrid, 2024*

**AIM:** To evaluate the results in terms of overall survival (OS) and local control of intraoperative electron radiotherapy (IOERT) delivered by standard linear accelerators or mobile lineal accelerators (LIAC) during breast conservative surgery for early breast cancer (EBC).

**PATIENTS AND METHODS:** 172 patients were treated from 2009 to 2023. According to results of sentinel lymph nodes biopsy, 110 patients received a single dose of 2100 cGy (N0) and 62 (N+) were treated with an electron boost (1000 cGy) followed by external beam radiotherapy. We used SPSS 29 for descriptive analysis and calculate 10-year OS using Kaplan Meier estimate.

**RESULTS:** The median age at diagnosis was 68 (42-87). Pathologic stages were I (80%) and II (19,2%). Subtype Luminal A and B were 86% and 13% respectively. Electron energies ranged from 6 MeV (58%) to 12 (8%) MeV. Most frequent applicator diameter used was 5cm (64%) and the most frequent bevel angle was 0° (62.2%). Metallic internal patient-shielding was used in 71% of procedures. Median time for wound healing was less than 15 days in 159 (92.4%) patients. There were no surgical complications in 79.65%. We observed lyponecrosis in 16 patients (9.3%). There were 4 local relapses (3 breast recurrences and 1 axillary) and 3 patients were diagnosed with distant metastasis. With a median follow-up of 84 months, we obtained a 10-year OS of 88% (non-cancer-related death).

**CONCLUSIONS:** After 15 years of institutional experience, IOERT in early-stage breast cancer has shown low toxicity, excellent local control and promising OS outcomes.

### REFERENCES

- Miranda FA, Teixeira LAB, Heinzen RN, de Andrade FEM, Hijal T, Buchholz TA, Moraes FY, Poortmans P, Marta GN. Accelerated partial breast irradiation: Current status with a focus on clinical practice. *Breast J*. 2019 Jan;25(1):124-128. doi: 10.1111/tbj.13164. Epub 2018 Dec 7. PMID: 30525258.
- Rodríguez N, Sanz X, Dengra J, Foro P, Membrive I, Reig A, Quera J, Fernández-Velilla E, Pera Ó, Lio J, Lozano J, Algara M. Five-year outcomes, cosmesis, and toxicity with 3-dimensional conformal external beam radiation therapy to deliver accelerated partial breast irradiation. *Int J Radiat Oncol Biol Phys*. 2013 Dec 1;87(5):1051-7. doi: 10.1016/j.ijrobp.2013.08.046. Epub 2013 Oct 22. PMID: 24161420.
- Sperk E, Astor D, Keller A, Welzel G, Gerhardt A, Tuschy B, Sütterlin M, Wenz F. A cohort analysis to identify eligible patients for intraoperative radiotherapy (IOERT) of early breast cancer. *Radiat Oncol*. 2014 Jul 12;9:154. doi: 10.1186/1748-717X-9-154. PMID: 25015740; PMCID: PMC4105865.
- Silverstein MJ, Fastner G, Maluta S, Reitsamer R, Goer DA, Vicini F, Wazer D. Intraoperative radiation therapy: a critical analysis of the ELIOT and TARGIT trials. Part 1--ELIOT. *Ann Surg Oncol*. 2014 Nov;21(12):3787-92. doi: 10.1245/s10434-014-3998-6. Epub 2014 Aug 27. PMID: 25160734; PMCID: PMC4189005.
- Deneve JL, Hoefler RA Jr, Harris EE, Laronga C. Accelerated partial breast irradiation: a review and description of an early North American surgical experience with the intrabeam delivery system. *Cancer Control*. 2012 Oct;19(4):295-308. doi: 10.1177/107327481201900406. PMID: 23037497.
- Marta GN, Macedo CR, Carvalho Hde A, Hanna SA, da Silva JL, Riera R. Accelerated partial irradiation for breast cancer: systematic review and meta-analysis of 8653 women in eight randomized trials. *Radiother*

Oncol. 2015 Jan;114(1):42-9. doi: 10.1016/j.radonc.2014.11.014. Epub 2014 Dec 2. Erratum in: Radiother Oncol. 2015 Jun;115(3):436-7. PMID: 25480094.

Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. *Lancet*. 2019 Dec 14;394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0. Epub 2019 Dec 5. PMID: 31813636; PMCID: PMC7199428.